RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 8 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 79 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed pancreatic ductal adenocarcinoma;

    Inclusion criterion 3

    Postoperative pathological stage (pTNM): T1-3, N0-2, M0;

    Inclusion criterion 5

  3. ECOG performance status score 0-1;

    Inclusion criterion 10

  4. Positive serology for HIV, Treponema pallidum or HCV;

    Exclusion criterion 8

    Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin;

    Exclusion criterion 22

  5. Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy;

    Inclusion criterion 12

    Pregnant or lactating women;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05911217, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntary participation in the clinical trial; fully understand, be informed about this study and have signed the ICF; willing to follow and able to complete all study procedures;
  • Aged 18 to 79 years;
  • Histologically confirmed pancreatic ductal adenocarcinoma;
  • Macroscopic complete tumor removal ;
  • Postoperative pathological stage (pTNM): T1-3, N0-2, M0;
  • Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive;
  • Subjects had recovered from surgery and had received months of standard adjuvant therapy;
  • Abnormal of Specific tumor marker level;
  • With sufficient venous access for leukapheresis collection;
  • ECOG performance status score 0-1;
  • Adequate organ function;
  • Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy;

Exclusion Criteria:

  • Prior neoadjuvant therapy for pancreatic cancer;
  • Subjects with borderline resectable pancreatic cancer;
  • Present or past history of metastatic or locally recurrent pancreatic cancer;
  • Evidence of malignant ascites;
  • Subjects had diseases that may interfere with CA19-9 level.
  • Toxicities caused by previous treatment have not recovered to CTCAE ≤ grade 2, except alopecia and other tolerable events as judged by the investigator or laboratory abnormalities allowed in this study;
  • Pregnant or lactating women;
  • Positive serology for HIV, Treponema pallidum or HCV;
  • Any active infections;
  • Clinically significant thyroid dysfunction;
  • Previous allergy to immunotherapy and related drugs, allergy to CT041 ingredients and other serious allergic history;
  • Subjects who may be at high risk for potential digestive tract bleeding or perforation;
  • Known active autoimmune disease, including but not limited to, psoriasis or rheumatoid arthritis, or other conditions requiring long-term immunosuppressive therapy;
  • Subjects who have a history of organ transplantation or are awaiting organ transplantation;
  • Subjects who require anticoagulant therapy;
  • Subjects who are receiving or are expected to require long-term antiplatelet therapy during the study;
  • Subjects who have experienced major surgery or have significant trauma within 4 weeks before apheresis, or who are expected to undergo major surgery during the study period;
  • Previously received any gene-modified cell therapies (including CAR T, TCR T);
  • Subjects who have other serious diseases that may restrict them from participating in the study assessed by investigators;
  • Subjects with oxygen saturation ≤ 95%;
  • Subjects who have signs of central nervous system diseases or clinically significant neurological examination abnormalities;
  • Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin;
  • Vaccination with live attenuated vaccines within 4 weeks prior to apheresis or planned during the study;
  • Subjects who are unable to or unwilling to comply with the requirements of the study protocol as assessed by investigators.

Quoted from ClinicalTrials.gov, NCT05911217, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05911217, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05911217